Ajay Pazhayattil

A structured assessment process can determine compliance to lifecycle process-validation requirements for biopharmaceuticals.

483s and Warning Letters Point to Inadequate Quality Oversight

FDA’s focus on the quality culture and its request for quality metrics may ensure a successful company-CMO relationship.